Merck cedes rights to Parkinson's compounds licensed from Addex

09/5/2011 | PharmaTimes (U.K.)

Merck & Co. ended a partnership with Addex Pharmaceuticals involving the latter's positive allosteric modulators of metabotropic glutamate receptor 4 to treat Parkinson's disease. The licensing deal was formed in 2007 and worth at least $106.5 million in milestone fees. Addex remains committed to developing the compounds for Parkinson's and other indications, said CEO Bharatt Chowrira.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Abbott
Chicago, IL
Senior Manager, Compliance
Stryker
Fremont, CA
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA